Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.52 CAD | -2.76% | -4.09% | -10.89% |
Jun. 07 | Transcript : HLS Therapeutics Inc. - Shareholder/Analyst Call | |
May. 28 | HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study | MT |
Sales 2024 * | 58.06M 79.71M | Sales 2025 * | 64.72M 88.83M | Capitalization | 81.73M 112M |
---|---|---|---|---|---|
Net income 2024 * | -18M -24.71M | Net income 2025 * | -13M -17.85M | EV / Sales 2024 * | 1.41 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.26 x |
P/E ratio 2024 * |
-4.31
x | P/E ratio 2025 * |
-6.12
x | Employees | 91 |
Yield 2024 * |
5.68% | Yield 2025 * |
-
| Free-Float | 99.93% |
Latest transcript on HLS Therapeutics Inc.
1 day | -2.76% | ||
1 week | -4.09% | ||
Current month | -5.38% | ||
1 month | -10.43% | ||
3 months | -17.76% | ||
6 months | -5.12% | ||
Current year | -10.89% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 56 | 23-04-30 |
John Hanna
DFI | Director of Finance/CFO | - | 23-06-21 |
Ryan Lennox
CMP | Compliance Officer | 43 | 18-05-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Welborn
CHM | Chairman | 46 | 21-06-17 |
Laura Brege
BRD | Director/Board Member | 66 | 19-03-20 |
John Hanna
DFI | Director of Finance/CFO | - | 23-06-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-12 | 3.52 | -2.76% | 10,900 |
24-06-11 | 3.62 | +1.97% | 1,414 |
24-06-10 | 3.55 | -2.74% | 864 |
24-06-07 | 3.65 | +2.82% | 700 |
24-06-06 | 3.55 | -3.27% | 1,000 |
Delayed Quote Toronto S.E., June 12, 2024 at 03:11 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.89% | 83.58M | |
+26.31% | 76.86B | |
-1.79% | 24.12B | |
+5.87% | 8.71B | |
+11.36% | 8.57B | |
-23.95% | 7.67B | |
+15.02% | 5.25B | |
+1.51% | 4.12B | |
-8.25% | 3.88B | |
+17.02% | 3.55B |
- Stock Market
- Equities
- HLS Stock